Nkarta | BiotechTV

top of page

BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions

He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs....

Company News

Jun 17

Nkarta CEO Paul Hastings on NK based cell therapies for autoimmune conditions

Paul Hastings describes why Nkarta believes NK based therapies are uniquely fit for this area.

Company News

Mar 27, 2024

BIO Chairman and Nkarta CEO talks biotech

Current BIO Chairman and Nkarta CEO Paul Hastings talks about the policy changes that have been affecting biotech lately, and NK cells.

Company News

Apr 27, 2023

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions

Nkarta CEO Paul Hastings on NK based cell therapies for autoimmune conditions

BIO Chairman and Nkarta CEO talks biotech

Follow BiotechTV

Sponsors

Sponsor Spotlight